Our CEO's strong IT background and a corporate belief that technology must drive execution inspired Tower to develop an extremely sophisticated technology — the Tower MSP Automation Suite — to manage every aspect of our proactive business processes. The suite consolidates our more than 50 years of compliance expertise into the latest, proven technologies.
Tower's fully integrated MSP Automation Suite identifies barriers to settlement and prompts resolutions as it tracks each claim from intake to closure and provides end-to-end visibility into the claim's progress. We proactively intervene to address unnecessary medical costs and inappropriate drug usage and obtain the evidence needed for CMS approval before preparing the MSA.
We are the only company in our industry with a single point of contact through every step in the process. We remain involved until the closure of your claim and pride ourselves making the process easy for our clients. We are with you every step of the way.
Pain management physician dispensed Pennsaid 1.5% (Diclofenac Sodium) for low back pain. Adjuster was not aware that medication had been prescribed as patient was given sample dose followed by paper prescription. Pennsaid did not effectively manage pain so injured worker did not fill the RX. According to CMS guidelines, medications listed as active by the treating physician will be included in the MSA whether or not the drugs are being filled by the patient. Total MSA - $970,355.
Tower’s Physician Follow-Up team worked with the assigned nurse to contact the treating physician’s office to communicate that the injured worker was not filling Pennsaid 1.5% noting that the medication did not manage pain effectively. Physician agreed to discontinue Pennsaid 1.5% and replace with oral Diclofenac. A letter was sent to confirm discontinuation.
Once updated to exclude the prescription drugs listed above, total MSA allocation was reduced to $19,166 and submitted to CMS. In its review, CMS accepted Tower’s physician letter as evidence of discontinuation of the medications listed and approved the MSA in full. This resulted in a savings of $951,189.
MSA Cost Savings from Clinical Intervention
Average Conditional Payments Savings
Pre-Validation Checks
Conditional Payments Reduced to $0
Your source for industry leading insight & information
Apparent Change in CMS Policy Expands Inclusion of Lyrica in MSAs
Lyrica is a brand name only medication which costs $8.91 per pill at 150mg. Over a 20-year life expectancy, this is ...
On 10/1/2018, the Centers for Medicare and Medicaid Services (CMS) released updates to the Workers’ Compensation Medicare Set-Aside (WCMSA) Reference Guide, ...
Tower Publishes White Paper on Medicare and Future Medical Considerations in Liability Settlements
CMS has signaled its intent to expand its voluntary WCMSA review program to liability. While a liability review policy has ...
The trusted source for the latest news in workers’ compensation, WorkCompCentral.com, hosts the leading innovators in Medicare Set-Aside development ...
Tower MSA Partners Sponsored WCI-TV Highlights WC Leaders at the 2018 WCI Conference
Tower MSA Partners was pleased to once again sponsor WCI-TV at the recently concluded 2018 WCI Educational Conference. Following last year’...
NAMSAP Bulletin Highlights Meeting with CMS on Liability MSA Reviews
Recently, the National Alliance of Medicare Set-Aside Professionals (NAMSAP) released a Special Edition Bulletin providing insight into a meeting between ...